These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30826661)

  • 41. Comprehensive analysis of coagulation indices for predicting survival in patients with biliary tract cancer.
    Ke X; Jin B; You W; Chen Y; Xu H; Zhao H; Lu X; Sang X; Zhong S; Yang H; Mao Y; Du S
    BMC Cancer; 2021 Aug; 21(1):953. PubMed ID: 34433454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
    Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Oncology; 2012; 83(2):57-66. PubMed ID: 22760079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
    Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
    Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.
    Zaanan A; Williet N; Hebbar M; Dabakuyo TS; Fartoux L; Mansourbakht T; Dubreuil O; Rosmorduc O; Cattan S; Bonnetain F; Boige V; Taïeb J
    J Hepatol; 2013 Jan; 58(1):81-8. PubMed ID: 22989572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A PET-based nomogram for oropharyngeal cancers.
    Castelli J; Depeursinge A; Ndoh V; Prior JO; Ozsahin M; Devillers A; Bouchaab H; Chajon E; de Crevoisier R; Scher N; Jegoux F; Laguerre B; De Bari B; Bourhis J
    Eur J Cancer; 2017 Apr; 75():222-230. PubMed ID: 28237868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy.
    Amit U; Shagun M; Plastaras JP; Metz JM; Karasic TB; Lubas MJ; Ben-Josef E
    Radiat Oncol; 2024 Aug; 19(1):102. PubMed ID: 39090660
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer.
    Lagenfelt H; Blomstrand H; Elander NO
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liver Oligometastasis in Biliary Tract Cancer and Impact on Survival Outcomes.
    Okamoto T; Takeda T; Sasaki T; Inoue Y; Mie T; Hirai T; Ishitsuka T; Yamada M; Nakagawa H; Furukawa T; Kasuga A; Ozaka M; Takahashi Y; Sasahira N
    J Gastrointest Cancer; 2024 Dec; 55(4):1530-1540. PubMed ID: 39145915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index.
    Rovesti G; Leone F; Brandi G; Fornaro L; Scartozzi M; Niger M; Yoo C; Caputo F; Filippi R; Casagrande M; Silvestris N; Santini D; Faloppi L; Palloni A; Aglietta M; Vivaldi C; Cho H; Lai E; Fenocchio E; Nichetti F; Pella N; De Lorenzo S; Di Maio M; Vasile E; de Braud F; Jeong JH; Aprile G; Orsi G; Cascinu S; Casadei-Gardini A
    J Gastrointest Cancer; 2022 Jun; 53(2):289-298. PubMed ID: 33544375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index.
    Rovesti G; Leone F; Brandi G; Cesario S; Scartozzi M; Niger M; Yoo C; Filippi R; Casagrande M; Silvestris N; Santini D; Faloppi L; Palloni A; Aglietta M; Bernardini L; Cho H; Lai E; Fenocchio E; Pircher C; Iacono D; De Lorenzo S; Sperti E; Massa V; De Braud F; Jeong JH; Aprile G; Burgio V; Cascinu S; Casadei-Gardini A
    J Gastrointest Cancer; 2022 Sep; 53(3):528-536. PubMed ID: 34033000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology).
    İnal A; Kos FT; Algın E; Yıldız R; Berk V; Unek İT; Colak D; Dane F; Geredeli C; Isıkdogan A
    Contemp Oncol (Pozn); 2015; 19(2):125-9. PubMed ID: 26034390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A population based analysis of prognostic factors in advanced biliary tract cancer.
    Peixoto RD; Renouf D; Lim H
    J Gastrointest Oncol; 2014 Dec; 5(6):428-32. PubMed ID: 25436121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cholangiocarcinoma: the quest for a second-line systemic treatment.
    Vienot A; Neuzillet C
    Transl Cancer Res; 2019 Apr; 8(Suppl 3):S275-S288. PubMed ID: 35117107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy.
    Salati M; Marcheselli L; Messina C; Merz V; Messina M; Carotenuto P; Caputo F; Gelsomino F; Spallanzani A; Reggiani Bonetti L; Caramaschi S; Luppi G; Dominici M; Ghidini M
    Cancer Manag Res; 2022; 14():983-993. PubMed ID: 35283642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score.
    Müller L; Mähringer-Kunz A; Jungmann F; Tanyildizi Y; Bartsch F; Czauderna C; Düber C; Galle PR; Weinmann A; Kloeckner R; Hahn F
    J Oncol; 2020; 2020():6180613. PubMed ID: 32684933
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protein Signatures and Individual Circulating Proteins, including IL-6 and IL-15, Associated with Prognosis in Patients with Biliary Tract Cancer.
    Christensen TD; Madsen K; Maag E; Larsen O; Jensen LH; Hansen CP; Markussen A; Høgdall DTS; Chen IM; Nielsen D; Johansen JS
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response to the letter by Buldukoglu et al. regarding our manuscript "Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation".
    Takaoka S; Hamada T; Nakai Y; Yasunaga H; Fujishiro M
    J Gastroenterol; 2024 Oct; 59(10):960-961. PubMed ID: 39107486
    [No Abstract]   [Full Text] [Related]  

  • 60. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
    Neuzillet C; Casadei-Gardini A; Brieau B; Vivaldi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Le Sourd S; Evesque L; Meurisse A; Lièvre A; Vernerey D; ;
    Int J Cancer; 2020 Dec; 147(11):3177-3188. PubMed ID: 32525595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.